Zenith Capital (Zenith Capital) FCF Yield % : -23.40 (As of May. 22, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Zenith Capital FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Zenith Capital's Trailing 12-Month Free Cash Flow is $-3.36 Mil, and Market Cap is $14.37 Mil. Therefore, Zenith Capital's FCF Yield % for today is -23.40%.

The historical rank and industry rank for Zenith Capital's FCF Yield % or its related term are showing as below:

ZHCLF' s FCF Yield % Range Over the Past 10 Years
Min: -23.4 Med: 0 Max: 0
Current: -23.4

ZHCLF's FCF Yield % is not ranked
in the Biotechnology industry.
Industry Median: -14.16 vs ZHCLF: -23.40

Zenith Capital's FCF Margin % for the quarter that ended in . 20 was 0.00%.

Zenith Capital FCF Yield % Historical Data

The historical data trend for Zenith Capital's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenith Capital FCF Yield % Chart

Zenith Capital Annual Data

Trend

FCF Yield %

Zenith Capital Quarterly Data

FCF Yield %

Competitive Comparison of Zenith Capital's FCF Yield %

For the Biotechnology subindustry, Zenith Capital's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zenith Capital's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zenith Capital's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Zenith Capital's FCF Yield % falls into.

Zenith Capital FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Zenith Capital's FCF Yield % for the fiscal year that ended in . 20 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=		/
	=	N/A%

Zenith Capital's annualized FCF Yield % for the quarter that ended in . 20 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=		*	4	/
	=	N/A%

Zenith Capital FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Zenith Capital FCF Yield % Related Terms

Thank you for viewing the detailed overview of Zenith Capital's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Zenith Capital (Zenith Capital) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenith Capital Corp (OTCPK:ZHCLF) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

300, 4820 RIchard Road SW, Calgary, AB, CAN, T3E 6L1

Website

Zenith Capital Corp is a biotechnology investment company. The company operates through its wholly-owned subsidiary Zenith Epigenetics Ltd. It is a clinical-stage biotechnology company focused on discovering and developing novel therapeutics. The company is developing various novel combinations of BET inhibitors with other targeted agents. Its lead compound, ZEN-3694, is in clinical development for metastatic Castration Resistant Prostate Cancer (mCRPC) in collaboration with Astellas and Newsoara and in metastatic triple-negative breast cancer.

Zenith Capital (Zenith Capital) Headlines

No Headlines